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ExtEndEd rEport
Secukinumab improves active psoriatic arthritis 
symptoms and inhibits radiographic progression: 
primary results from the randomised, double-blind, 
phase III FUTURE 5 study
philip Mease,1 désirée van der Heijde,2 robert Landewé,3 Shephard Mpofu,4 
proton rahman,5 Hasan tahir,6 Atul Singhal,7 Elke Boettcher,8 Sandra navarra,9 
Karin Meiser,4 Aimee readie,10 Luminita pricop,10 Ken Abrams10
AbstrACt
Objectives to evaluate the effect of subcutaneous 
(s.c.) secukinumab, an interleukin-17A inhibitor, 
on clinical signs and symptoms and radiographic 
progression in patients with psoriatic arthritis (psA).
Methods Adults (n=996) with active psA were 
randomised 2:2:2:3 to s.c. secukinumab 300 mg 
or 150 mg with loading dose (Ld), 150 mg without 
Ld or placebo. All groups received secukinumab or 
placebo at baseline, weeks 1, 2 and 3 and then every 
4 weeks from week 4. the primary endpoint was the 
proportion of patients achieving an American College 
of rheumatology 20 (ACr20) response at week 16.
results Significantly more patients achieved an 
ACr20 response at week 16 with secukinumab 
300 mg with Ld (62.6%), 150 mg with Ld (55.5%) 
or 150 mg without Ld (59.5%) than placebo (27.4%) 
(p<0.0001 for all; non-responder imputation). 
radiographic progression, as measured by van der 
Heijde-modified total Sharp score, was significantly 
inhibited at week 24 in all secukinumab arms versus 
placebo (p<0.01 for 300 mg with Ld and 150 mg 
without Ld and p<0.05 for 150 mg with Ld; linear 
extrapolation). Adverse event rates at week 24 were 
similar across treatment arms: 63.1% (300 mg with 
Ld), 62.7% (150 mg with Ld), 61.1% (150 mg without 
Ld) and 62.0% (placebo). no deaths or new safety 
signals were reported.
Conclusion S.c. secukinumab 300 mg and 150 mg 
with and without Ld significantly improved clinical 
signs and symptoms and inhibited radiographic 
structural progression versus placebo at week 24 in 
patients with psA.
trial registration number nCt02404350; results.
IntrOduCtIOn
Psoriatic arthritis (PsA) is a chronic, inflammatory 
disease characterised by peripheral arthritis, axial 
disease, dactylitis, enthesitis and skin and nail 
psoriasis.1 2 It can have a substantial impact on 
quality of life and work productivity,3 with many 
patients experiencing irreversible joint damage 
and disability.1 4 Indeed, bone erosions occur in 
approximately half of patients within 2 years.5 
Enhanced understanding of the pathophys-
iology of PsA has aided the development of 
targeted therapies to manage its signs and symp-
toms. The proinflammatory cytokine interleukin 
(IL)-17A mediates multiple biological functions 
that result in joint and entheseal inflammation, 
damage and tissue remodelling, which are char-
acteristic of PsA.6–8 Recommendations from the 
European League Against Rheumatism (EULAR)9 
and the Group for Research and Assessment of 
Psoriasis and Psoriatic Arthritis (GRAPPA)10 
recognise targeting IL-17A as a therapeutic 
strategy to manage all the main clinical domains 
of PsA.
Secukinumab, a fully human monoclonal antibody 
that selectively neutralises IL-17A,11 is approved in 
many countries for the treatment of PsA, psoriasis 
and ankylosing spondylitis. There is now an exten-
sive body of evidence involving more than 2700 
patients demonstrating the efficacy of secukinumab 
in PsA.12–18 Data from the phase III studies, FUTURE 
1 and FUTURE 2, have shown that secukinumab 
provides rapid and significant improvements in the 
signs and symptoms of PsA that are sustained for 
up to 3 years of therapy.12–18 These clinical benefits 
have been observed in patients naïve to biological 
therapy and in those with an intolerance or inade-
quate response to agents targeting tumour necrosis 
factor (TNF).9 10 13–18 Data from FUTURE 1 have 
shown that secukinumab significantly inhibits joint 
structural damage through 24 weeks,13 with bene-
fits maintained out to 2 years.17 FUTURE 1 used 
an intravenous loading followed by subcutaneous 
(s.c.) dosing regimen for secukinumab and did not 
evaluate a dose higher than 150 mg.13 FUTURE 2 
used s.c. loading and maintenance dosing of secuk-
inumab 300, 150 and 75 mg14 (the 300 and 150 mg 
dosing regimens were subsequently adopted as the 
approved regimens in PsA), but it did not examine 
radiographic progression and, until now, these data 
have been lacking. Here, we report primary results 
from the ongoing FUTURE 5 study, the largest 
randomised, controlled study to date of a biologic 
in PsA. The study was designed to evaluate the 
impact of s.c. secukinumab 300 and 150 mg on clin-
ical signs and symptoms and radiographic progres-
sion as well as evaluating the short-term benefit of 
the loading regimen. This trial is ongoing and will 
provide long-term data out to 2 years.
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MetHOds
study design and participants
FUTURE 5 (NCT02404350) is a randomised, double-blind, 
placebo-controlled, parallel-group phase III trial. The study 
design is shown in online supplementary figure 1. The study was 
conducted in accordance with the principles of the Declaration 
of Helsinki.19 Patients provided written informed consent before 
study-related procedures were undertaken.
Patients were aged ≥18 years and met the ClASsification 
criteria for Psoriatic ARthritis2 at screening, with symptoms of 
moderate-to-severe PsA for at least 6 months: ≥3 tender joints 
and ≥3 swollen joints despite ≥4 weeks of treatment with 
non-steroidal anti-inflammatory drugs (NSAIDs), or an intol-
erance to them, and active or documented history of plaque 
psoriasis or psoriatic nail changes. Concomitant corticosteroids 
(≤10 mg/day prednisone or equivalent), NSAIDs and metho-
trexate (≤25 mg/week) were allowed, provided the dose was 
stable and remained so for the first 24 weeks of the study. 
Patients who had previously used anti-TNF agents could enrol if 
they had experienced an inadequate response or stopped treat-
ment due to safety or intolerance (anti-TNF-IR). Patients taking 
anti-TNF therapy and/or a disease-modifying antirheumatic drug 
other than methotrexate required a washout ranging from 4 to 
10 weeks before randomisation, depending on the prohibited 
treatment used. Key exclusion criteria included active/history of 
ongoing infection, prior use of a biologic other than an anti-TNF 
agent, use of ≥3 anti-TNF agents and active inflammatory 
disease other than PsA.
treatment and randomisation
Following a screening period of up to 10 weeks, Interactive 
Response Technology was used to randomly assign eligible 
patients in a 2:2:2:3 ratio to one of four treatment groups: 
secukinumab 300 mg with loading dose (LD), secukinumab 
150 mg with LD, secukinumab 150 mg without LD or placebo, 
all administered s.c. (online supplementary figure 1). Patients 
self-administered their own treatment using prefilled syringes at 
baseline, weeks 1, 2 and 3 followed by treatment every 4 weeks 
from week 4. Patients in the secukinumab 150 mg without LD 
arm were administered placebo at weeks 1, 2 and 3 to conceal 
treatment allocation. At week 16, patients in the placebo arm 
with <20% improvement from baseline in tender and swollen 
joint counts (SJCs) were switched in a double-blind manner to 
receive s.c. secukinumab 300 mg or 150 mg, preassigned at orig-
inal randomisation. Remaining patients in the placebo arm were 
switched to blinded secukinumab 300 mg or 150 mg at week 24.
Randomisation was stratified according to previous anti-TNF 
therapy use, with patients being anti-TNF-naïve (planned enrol-
ment about 70%) or anti-TNF-IR. Patients, investigators and 
assessors remain masked to the treatment assignment until all 
patients reach week 52.
Outcomes
The primary efficacy endpoint was the proportion of patients 
with an American College of Rheumatology 20 (ACR20) 
response at week 16. The key secondary hierarchical endpoint 
was radiographic structural progression at week 24, as measured 
by change from baseline in van der Heijde-modified total Sharp 
score (vdH-mTSS), which ranges from 0 to 528 (higher scores 
indicating more articular damage)20 based on independent assess-
ments of hand/wrist/foot radiographs obtained at baseline, week 
16 (non-responders) and week 24 by two central blinded readers 
(plus an adjudicator if required). Other hierarchical secondary 
endpoints were assessed at week 16 and included: propor-
tion of patients achieving a 75% or 90% improvement from 
baseline in the Psoriatic Area and Severity Index (PASI75 and 
PASI90, respectively);21 proportion of patients with an ACR50 
response; change from baseline on the Health Assessment Ques-
tionnaire-Disability Index (HAQ-DI scores range from 0 to 3 
with higher scores indicate greater disability);22 change from 
baseline in the 28-joint Disease Activity Score using C reactive 
protein (DAS28-CRP, with higher scores indicating more active 
disease);23 and resolution of enthesitis and dactylitis. Definitions 
of the ACR20 response and secondary points used in the study 
are provided in the online supplementary methods.
Prespecified exploratory endpoints of ACR70 response, the 
proportion of patients with no structural progression (change 
from baseline in vdH-mTSS ≤0.5) at week 24 and both the 
primary endpoint (ACR20 at week 16), change from baseline 
vdH-mTSS at week 24 by prior use of anti-TNF therapy and 
the proportion of patients achieving minimal disease activity 
(MDA) are also reported. MDA is assessed as five of the seven 
following: ≤1 tender joint count, ≤1 SJC, PASI≤1 or body 
surface area (BSA)≤3%, patient pain visual analogue score 
(VAS)≤15, patient global assessment of disease activity VAS≤20, 
HAQ-DI≤0.5, tender entheseal points≤1.24 Disease Activity 
index for PSoriatic Arthritis (DAPSA) was analysed posthoc. 
DAPSA is a continuous index, calculated by summing of indi-
vidual scores for: (1) tender joint count (TJC), (2) SJC, (3) 
patient global assessment, (4) patient assessment of pain and 
(5) CRP level, using 66/68 joint counts.25 DAPSA ranges from 
0 to 164; DAPSA remission (REM; range 0–4) and low disease 
activity (LDA; range 5–14) were assessed. Overall safety and 
tolerability of secukinumab over the 24 weeks was assessed by 
monitoring adverse events (AEs), serious AEs (SAEs), laboratory 
assessments and vital signs.
statistical analyses
Sample sizes were calculated based on an overall two-sided 5% 
type I error rate. As three secukinumab regimens were tested 
versus placebo for ACR20, the type I error was separated into 
a 1.67% two-sided for each comparison. Based on ACR20 
response rates of previous studies,14 a sample size of 220 patients 
in each secukinumab group, and 330 in the placebo group was 
estimated to provide around 99% power (for all three dose regi-
mens) to detect a treatment difference in the primary endpoint 
(ACR20 at week 16) based on Fisher’s exact test.
For the key secondary endpoint, radiographic structural 
progression (vdH-mTSS), a treatment difference of 0.52 and 
SD of 1.13 with active treatment and 2.44 with placebo were 
observed in historical data.13 Based on these assumptions, there 
is 83% power to detect a treatment difference using Satterth-
waite t-test.
A sequential hierarchical testing method (online supplemen-
tary figure 2) was used to maintain the familywise type I error 
rate at 5% across the primary and ranked secondary specified 
endpoints. P values were calculated as 2-sided. Patients were 
analysed according to randomised treatment.
Statistical analyses were based on logistic regression for binary 
efficacy variables (eg, ACR20/50/70 and so on), non-para-
metric analysis of covariance for radiographic data (if baseline 
and ≥1 postbaseline radiographic assessments were available) 
and mixed-effects models for repeated measures (MMRM) for 
continuous variables (eg, DAS28-CRP, HAQ-DI). All models 
fitted included anti-TNF status, weight and the corresponding 
baseline value as a covariate as well as treatment as a factor (time, 
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treatment by time and baseline by time interaction were also 
used for MMRM models). Missing values and placebo patients 
rescued at week 16 were imputed as non-responders for binary 
endpoints (rescue penalty), linear extrapolation was applied for 
radiographic data (if baseline and week 16 values were available) 
and the missing at random assumption of the MMRM analysis 
was applied for continuous endpoints.
Safety endpoints were assessed for all patients who 
received ≥1 dose of study drug and were summarised descrip-




A total of 996 patients were randomly assigned to receive secuk-
inumab 300 mg with LD (n=222), secukinumab 150 mg with 
LD (n=220), secukinumab 150 mg without LD (n=222) or 
placebo (n=332). At week 24, a total of 66 (6.9%) patients had 
discontinued, with the greatest number (n=37) coming from 
the placebo group. The most common reason for discontinua-
tion was patient/guardian decision (3.2% overall; 5.7% placebo, 
3.2% 150 mg without LD and 1.4% for both 150 mg and 300 mg 
with LD) followed by AEs (1.6% overall; 2.7% placebo, 0.9% 
150 mg each with and without LD, and 1.4% 300 mg with LD). 
Patient disposition is shown in online supplementary figure 3.
Demographics and baseline characteristics were balanced 
between treatment arms (table 1). Overall, the mean age was 
48.8 years, 49.8% were female and the mean time since PsA 
diagnosis was 6.6 years. At baseline, 70.4% of patients were 
anti-TNF-naïve and 50.1% were receiving concomitant metho-
trexate. Approximately half (51.6%) of the patients had psoriasis 
affecting ≥3% of their BSA. Enthesitis was present in 60.4% 
and dactylitis in 39.1% of patients. Mean swollen and tender 
joint counts were 11.5 and 21.0, respectively and mean HAQ-DI 
score was 1.3.
efficacy
The primary endpoint was met with all secukinumab doses. 
ACR20 response rates at week 16 were significantly higher 
with secukinumab 300 mg with LD (62.6%), 150 mg with LD 
(55.5%) or 150 mg without LD (59.5%) than placebo (27.4%; 
p<0.0001 for all doses vs placebo; figure 1, online supplemen-
tary table 1 and table 2). ACR50/70 response rates at week 
16 were also significantly higher with all secukinumab doses 
versus placebo (figure 1 and online supplementary table 1). 
ACR20/50/70 response rates at week 16 were numerically higher 
table 1 Demographics and baseline characteristics for the randomised set
Characteristic
secukinumab
300 mg with ld
(n=222)
secukinumab
150 mg with ld
(n=220)
secukinumab






Age (years), mean (SD) 48.9 (12.8) 48.4 (12.9) 48.8 (11.8) 49.0 (12.1) 48.8 (12.4)
Female, n (%) 114 (51.4) 109 (49.5) 102 (45.9) 171 (51.5) 496 (49.8)
Weight (kg) 81.9 (16.9) 83.3 (19.6) 84.1 (20.5) 84.1 (19.6) 83.4 (19.2)
Race, n (%)
  White 184 (82.9) 178 (80.9) 180 (81.1) 274 (82.5) 816 (81.9)
  Asian 24 (10.8) 29 (13.2) 27 (12.2) 33 (9.9) 113 (11.3)
  American Indian or Alaska Native 1 (0.5) 1 (0.5) 6 (2.7) 2 (0.6) 10 (1.0)
  Black or African American 1 (0.5) 0 (0.0) 0 (0.0) 5 (1.5) 6 (0.6)
  Unknown 0 (0.0) 0 (0.0) 2 (0.9) 2 (0.6) 4 (0.4)
  Other 12 (5.4) 12 (5.5) 7 (3.2) 16 (4.8) 47 (4.7)
Time since first diagnosis of psoriatic disease (years), mean (SD) 6.7 (8.3) 6.7 (7.1) 6.2 (6.1) 6.6 (7.6) 6.6 (7.3)
Number of prior anti-TNF therapies, n (%)
  0 154 (69.4) 155 (70.5) 158 (71.2) 234 (70.5) 701 (70.4)
  1 45 (20.3) 43 (19.5) 44 (19.8) 65 (19.6) 197 (19.8)
  ≥2 23 (10.4) 22 (10.0) 20 (9.0) 33 (9.9) 98 (9.8)
Methotrexate use at randomisation, n (%) 112 (50.5) 108 (49.1) 120 (54.1) 159 (47.9) 499 (50.1)
Systemic glucocorticoid at randomisation, n (%) 34 (15.3) 44 (20.0) 37 (16.7) 53 (16.0) 168 (16.9)
Patients with specific disease characteristics, n (%)
  Psoriasis affecting≥3% of BSA 110 (49.5) 125 (56.8) 117 (52.7) 162 (48.8) 514 (51.6)
  Presence of enthesitis 140 (63.1) 141 (64.1) 129 (58.1) 192 (57.8) 602 (60.4)
  Presence of dactylitis 82 (36.9) 80 (36.4) 103 (46.4) 124 (37.3) 389 (39.1)
Disease and quality of life scores, mean (SD)
  Tender joint count (78 joints) 19.8 (15.1) 21.2 (15.9) 21.8 (16.0) 21.2 (16.2) 21.0 (15.8)
  Swollen joint count (76 joints) 10.0 (8.0) 12.1 (10.5) 11.9 (10.3) 11.7 (10.8) 11.5 (10.1)
  DAS28-CRP score 4.5 (1.0) 4.7 (1.0) 4.6 (1.1) 4.6 (1.1) 4.6 (1.1)
  HAQ-DI score 1.2 (0.6) 1.3 (0.6) 1.3 (0.7) 1.3 (0.6) 1.3 (0.6)
  vdH-mTSS 12.9 (23.7) 13.6 (25.9) 15.3 (37.5) 15 (38.2) – 
  PsA pain, VAS 0–100 mm 52.8 (24.8) 56.5 (22.8) 54.5 (22.9) 53.6 (24.5) 54.3 (23.9)
  Patients’ global assessment of disease activity, VAS 0–100 mm 55.0 (22.8) 53.9 (22.6) 54.6 (23.5) 52.5 (22.2) 53.9 (22.7)
  Physician’s global assessment of disease activity, VAS 0–100 mm 55.4 (18.3) 57.7 (18.6) 57.3 (19.2) 54.3 (20.3) 55.9 (19.3)
BSA, body surface area; DAS28-CRP, 28-joint Disease Activity Score using C reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; LD, loading dose; PsA, 
psoriatic arthritis; TNF, tumour necrosis factor; VAS, visual analogue scale; vdH-mTSS, van der Heijde-modified total Sharp score.
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in anti-TNF-naive than anti-TNF-IR patients for all secukinumab 
doses. All secondary hierarchical endpoints were significant for 
secukinumab versus placebo at week 16, except for enthesitis and 
dactylitis resolution for the 150 mg without LD group (table 2, 
figure 2 and online supplementary table 2).
Mean changes from baseline in vdH-mTSS demonstrated 
significant inhibition of radiographic structural progression at 
week 24 in all secukinumab groups versus placebo: 0.08 (300 mg 
with LD; p<0.01), 0.17 (150 mg with LD; P<0.05), –0.09 (150 
mg without LD; p<0.05) versus 0.50 (placebo; figure 3, online 
supplementary table 3 and table 2). The proportion of patients 
with no radiographic structural progression at week 24, defined 
as ≤0.5 change from baseline in vdH-mTSS, was higher across 
all secukinumab dose regimens than placebo: 191/217 (88.0%) 
patients in the secukinumab 300 mg with LD group, 170/213 
(79.8%) in the 150 mg with LD group and 176/210 (83.8%) in 
the 150 mg without LD group versus 218/296 (73.6%) in the 
placebo group (online supplementary figure 4).
The 300 mg secukinumab dose provided numerically better 
efficacy in all hierarchical endpoints versus the 150 mg regi-
mens, with the strongest treatment difference observed for 
psoriasis improvement. PASI 75 response rates at week 16 were 
Figure 1 (A) ACR20, (B) ACR50 and (C) ACR70 response rates from baseline up to week 24a in the overall population and by anti-TNF status. 
*P<0.0001; †p<0.001; §p<0.01; ‡p<0.05 unadjusted p values versus placebo (Statistical analysis was based on logistic regression. Missing values 
and placebo patients rescued at week 16 were imputed as non-responders.) aThe primary endpoint was ACR20 response in the overall population at 
week 16. ACR20/50/70, ≥20/50/70% improvement from baseline in American College of Rheumatology response criteria; anti-TNF-IR, intolerance or 
inadequate response to antitumour necrosis factor therapy.
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70.0% with 300 mg with LD, 60.0% with 150 mg with LD, 
58.1% with 150 mg without LD and 12.3% with placebo; corre-
sponding PASI 90 responses rates were 53.6%, 36.8%, 31.6% 
and 9.3%, respectively. Treatment responses were greater in anti-
TNF-naïve patients than in anti-TNF-IR patients (Figures 1,3). 
In the 150 mg groups, patients receiving LD generally had an 
earlier onset of response and numerically greater efficacy versus 
patients without LD (figure 1).
The proportion of patients achieving MDA at week 16 were 
33.0% with secukinumab 300 mg, 28.2% with 150 mg with 
LD, 23.0% with 150 mg without LD and 8.4% with placebo 
(p<0.001 for all secukinumab doses versus placebo; online 
supplementary figure 5). The proportion of patients achieving 
DAPSA REM/LDA states at week 16 were 15.2%/37.4% with 
secukinumab 300 mg, 13.4%/27.8% with 150 mg with LD, 
9.0%/34.8% with 150 mg without LD and 2.3%/18.9% with 
placebo (online supplementary figure 5).
safety
Exposure and safety are reported in table 3. The duration of 
exposure over the 24 weeks was higher for secukinumab (329.7 
patient-years) than placebo (122.7 patient-years) due to 158 
patients in the placebo group switching to secukinumab at 
week 16. The most commonly reported AEs represented upper 
respiratory tract infections; other common AEs are reported 
in table 3. No deaths or major adverse cardiac events were 
reported. Non-fatal SAE rates were low overall and similar for 
secukinumab (3.0%) and placebo (3.6%). Most SAEs repre-
sented single events with no discernible pattern.
Selected SAEs of interest included: one report of suicidal 
thoughts in a patient with a history of anxiety who continued 
in the study without further episodes; one anaphylactic reac-
tion after the second secukinumab dose, which resulted in 
patient discontinuation; one new diagnosis of ulcerative 
colitis in a secukinumab patient with no prior gastrointestinal 
table 2 Comparison of secukinumab versus placebo at week 16 for prespecified hierarchical endpoints
secukinumab 300 mg 
with ld
(n=222)









  ACR20 response (%) 62.6*** 55.5*** 59.5*** 27.4
Prespecified secondary endpoints
  vdH-mTSS structural progression (mean change from BL)† 0.08** 0.17* −0.09* 0.50
  PASI 75 response (%)‡ 70.0* 60.0* 58.1* 12.3
  PASI 90 response (%)‡ 53.6* 36.8* 31.6* 9.3
  ACR50 response (%) 39.6* 35.9* 32.0* 8.1
  HAQ-DI score (LS mean change from BL) −0.55* −0.44* −0.45* −0.21
  DAS28-CRP score (LS mean change from BL) −1.49* −1.29* −1.29* −0.63
  Enthesitis resolution (%)§ 55.7* 54.6* 41.9 35.4
  Dactylitis resolution (%)¶ 65.9* 57.5* 56.3 32.3
*P<0.05; **p<0.01; ***p<0.0001 unadjusted p values versus  placebo are shown for endpoints that were significant in the hierarchical testing. 
†Week 24 data.
‡Data from patients with baseline psoriasis affecting ≥3 BSA.
§Data from patients with enthesitis at baseline.
¶Data from patients with dactylitis at baseline.
ACR20, American College of Rheumatology 20; BL, baseline; BSA, body surface area; DAS28-CRP, 28-joint Disease Activity Score using C reactive protein; HAQ-DI, Health 
Assessment Questionnaire-Disability Index; LD, loading dose; LS, least squares; PASI, Psoriasis Area and Severity Index; vdH-mTSS, van der Heijde-modified total Sharp score. 
Figure 2 Resolution of enthesitis and dactylitis in the overall population from baseline up to week 24a.*P<0.0001; †p<0.001; §p<0.01; 
‡p<0.05 unadjusted p values versus placebo. (Statistical analysis was based on logistic regression. Missing values and placebo patients rescued at 
week 16 were imputed as non-responders.) aResolution of dactylitis and enthesitis were not significant for secukinumab 150 mg without load in 
hierarchical testing.
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Figure 3 Change in vdH-mTSS from baseline at week 24 (non-parametric ANCOVA-linear extrapolation in the overall population and by anti-
TNF status. †P<0.001; §p<0.01; ‡p<0.05 unadjusted p values versus placebo (Statistical analysis was based on a non-parametric ANCOVA. Linear 
extrapolation was applied if a baseline and week 16 value were available). ANCOVA, analysis of covariance; anti-TNF-IR, intolerance or inadequate 
response to antitumour necrosis factor therapy; LD, loading dose; vdH-mTSS, van der Heijde-modified total Sharp score.
table 3 Exposure and rates of deaths, discontinuations, AEs, SAEs and selected AEs and SAEs of interest up to week 24†
Variable
secukinumab
300 mg with ld
(n=222)
secukinumab
150 mg with ld
(n=220)
secukinumab








  Patient-years 102.0 101.8 101.2 329.7 122.9
  Days (mean) 167.8 169.0 166.5 146.5 135.0
Death and AEs
  Death, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Discontinuation due to AE, n (%) 3 (1.4) 4 (1.8) 3 (1.4) 11 (1.3) 7 (2.1)
  Non-fatal SAE, n (%) 7 (3.2) 9 (4.1) 6 (2.7) 25 (3.0) 12 (3.6)
  Number of patients with any AE, n (%) 140 (63.1) 138 (62.7) 136 (61.3) 463 (56.3) 206 (62.0)
Most common AEs, n (%)‡
  Viral upper respiratory tract infection 14 (6.3) 15 (6.8) 13 (5.9) 44 (5.4) 29 (8.7)
  Upper respiratory tract infection 7 (3.2) 17 (7.7) 14 (6.3) 38 (4.6) 11 (3.3)
  Dyslipidaemia 8 (3.6) 4 (1.8) 8 (3.6) 23 (2.8) 11 (3.3)
  Headache 5 (2.3) 9 (4.1) 8 (3.6) 23 (2.8) 13 (3.9)
  Hypertension 8 (3.6) 5 (2.3) 9 (4.1) 22 (2.7) 10 (3.0)
  Diarrhoea 9 (4.1) 4 (1.8) 7 (3.2) 21 (2.6) 22 (6.6)
  Hypercholesterolaemia 3 (1.4) 9 (4.1) 8 (3.6) 20 (2.4) 2 (0.6)
  Urinary tract infection 6 (2.7) 8 (3.6) 6 (2.7) 20 (2.4) 8 (2.4)
Selected AEs of interest, n (%)
  Candida infection 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0)
  Oral candidiasis 2 (0.9) 1 (0.5) 0 (0.0) 3 (0.4) 1 (0.3)
  Vulvovaginal candidiasis 1 (0.5) 2 (0.9) 0 (0.0) 3 (0.4) 1 (0.3)
  Injections site reactions 6 (2.7) 5 (2.3) 3 (1.4) 15 (1.8) 4 (1.2)
Selected SAEs of interest, n (%)
  Crohn’s disease 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.1) 0 (0.0)
  Ulcerative colitis 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.1) 0 (0.0)
  Neoplasms benign, malignant and unspecified 0 (0.0) 0 (0.0) 1 (0.5)§ 2 (0.2)¶ 0 (0.0)
†Up to the data cut-off point for interim analysis.
‡AEs that occurred at an incidence rate of >2% in the ‘any secukinumab’ group. Any secukinumab group represents each originally randomised secukinumab patient plus 
patients who switched to active treatment at week 16 due to non-response.
§Bladder neoplasm reported as an non-serious AE (day 34).
¶Includes one case of melanoma (day 139) in a placebo patient switched to secukinumab (day 113).
AE, adverse event; LD, loading dose; SAE, serious adverse event.
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medical history and who remained in the study and one case 
of Crohn’s disease in a patient with a history of colitis. There 
was one mild, non-serious exacerbation of Crohn’s disease in 
a secukinumab-treated patient who continued on study treat-
ment and remained in the study; the event was resolved at the 
time of reporting.
Reports of Candida infections included: one case of oral 
thrush (300 mg with LD), four cases of oral candidiasis (one 
in 150 mg with LD; two in 300 mg with LD; one in placebo) 
and four cases of vulvovaginal candidiasis (two in 150 mg 
with LD; one in 300 mg; one in placebo). These were of mild 
severity, except one moderately severe vulvovaginal candida 
infection; all resolved with standard therapy. No systemic 
fungal infections or newly diagnosed tuberculosis infections 
were reported, and incidences of injection site reactions were 
low across all groups.
dIsCussIOn
FUTURE 5 is the largest randomised phase III trial to date of a 
biologic in PsA. In this study, s.c. administration of secukinumab 
300 mg and 150 mg provided rapid and significant improvement 
versus placebo in most clinical domains of PsA and inhibited 
radiographic progression at week 24.
The primary endpoint, ACR20 response at week 16, was met 
for all secukinumab regimens, and secondary endpoints were 
significant for all secukinumab doses except for enthesitis and 
dactylitis resolution in the 150 mg without LD group. These 
results confirm and extend previous findings relating to the effi-
cacy of secukinumab in PsA.12–18 In addition, clinical response 
rates (ACR20/50/70) at week 16 were higher in anti-TNF-naive 
patients than in those who were anti-TNF-IR for all secuki-
numab doses.
These data provide the first evidence that s.c. secukinumab 
loading and maintenance dosing regimens and the higher dose 
of 300 mg significantly inhibit joint structural damage in PsA. 
More patients who received secukinumab versus those who 
received placebo had no radiographic progression through week 
24. Inhibition of radiographic progression was observed in both 
anti-TNF-naïve and anti-TNF-IR patients, although statistical 
significance was not reached in the anti-TNF-IR population. The 
lack of significance could be affected by a number of factors, 
including the relatively small number of anti-TNF-IR patients 
and the heterogeneity of this subpopulation, which comprised 
patients who previously failed anti-TNF treatment for any one of 
several reasons, including lack of primary or secondary efficacy, 
intolerance or safety concerns.26 This study was limited in that 
it was not designed to identify a difference between doses or 
to assess differences in response according to previous anti-TNF 
use.
Patients enrolled in this study had a long duration of disease 
(mean around 6.5 years) and very active disease as evidenced 
by the relatively high tender and swollen joint scores and the 
large proportion of patients with enthesitis and dactylitis at 
baseline. Additionally, around 30% of patients had previously 
received one or more anti-TNF treatments before entering 
this trial. While anti-TNF agents have been shown to improve 
outcomes in PsA,27–31 many patients experience inadequate 
disease control, treatment intolerance or loss of response over 
time.1 32 In agreement with previous studies,9 10 13–18 secuki-
numab treatment in FUTURE 5 was shown to be efficacious 
in both anti-TNF-naïve and anti-TNF-IR patients, with clinical 
responses generally being higher in anti-TNF-naïve patients. 
These results confirm that secukinumab is a suitable treatment 
option for biologic-naïve patients and those who have previ-
ously failed anti-TNF therapy.
The secukinumab 300 mg dose consistently provided numer-
ically better responses versus the 150 mg dose, with or without 
LD, in clinical endpoints such as ACR20/50/70, resolution of 
enthesitis and dactylitis, HAQ-DI, DAS28-CRP, PASI 75 and PASI 
90, particularly in anti-TNF-IR patients. Data from FUTURE 5 
also demonstrate the benefit of a loading regimen in terms of 
providing an earlier onset of action, especially on higher efficacy 
endpoints such as ACR50/70, dactylitis and in the treatment of 
psoriasis symptoms, as indicated by PASI 75 and PASI 90, and 
in the proportion of patients achieving MDA and DAPSA-REM.
The safety profile was consistent with that previously reported 
for PsA12–18 and psoriasis.32 The types and incidences of most 
AEs with secukinumab were similar to those for placebo for the 
entire 24-week treatment period, without evidence of dose-de-
pendency. The rate of Candida infections was higher with 
secukinumab treatment than with placebo; this is consistent 
with previous reports13 14 and considered to be related to the 
role of IL-17 in mucocutaneous defence against Candida infec-
tions.33 No systemic fungal infections were reported. All cases 
of Candida infection resolved with standard oral therapy and 
patients continued in the study.
This study demonstrated that s.c. secukinumab 300 mg and 
150 mg provided significant inhibition of radiographic progres-
sion, and has demonstrated the benefit of a LD regimen (regard-
less of the dose), particularly when aiming for higher levels of 
response and faster outcomes in joint and skin endpoints. The 
safety profile of secukinumab was consistent with previous 
reports, with no new safety signals observed.12–18 FUTURE 5 
confirms and extends the results of previous data demonstrating 
the efficacy of s.c. administration of secukinumab in achieving 
comprehensive treatment goals in PsA.
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